Lopinavir/ritonavir in the treatment of HIV-1 infection: a review. - Wikidata - wikimedia - TriplyDB

Lopinavir/ritonavir in the treatment of HIV-1 infection: a review.

Lopinavir/ritonavir in the treatment of HIV-1 infection: a review.

http://www.wikidata.org/entity/Q37052827

about

Comparative efficacy versus effectiveness of initial antiretroviral therapy in clinical trials versus routine care Metabolic and neurologic consequences of chronic lopinavir/ritonavir administration to C57BL/6 mice In vitro activity of antiretroviral drugs against Plasmodium falciparum Novel strategies in the use of lopinavir/ritonavir for the treatment of HIV infection in children.Assessment of lopinavir pharmacokinetics with respect to developmental changes in infants and the impact on weight band-based dosing.Brain injury caused by HIV protease inhibitors: role of lipodystrophy and insulin resistance.No Need for Lopinavir Dose Adjustment during Pregnancy: a Population Pharmacokinetic and Exposure-Response Analysis in Pregnant and Nonpregnant HIV-Infected Subjects.Basis of selection of first and second line highly active antiretroviral therapy for HIV/AIDS on genetic barrier to resistance: a literature review Circumvention of P-gp and MRP2 mediated efflux of lopinavir by a histidine based dipeptide prodrug.The Glucose Transporter PfHT1 Is an Antimalarial Target of the HIV Protease Inhibitor Lopinavir.The HIV protease inhibitor lopinavir/ritonavir (Kaletra) alters the growth, differentiation and proliferation of primary gingival epithelium.Use of Adult Sensory Panel to Study Individual Differences in the Palatability of a Pediatric HIV Treatment Drug.High quality of life, treatment tolerability, safety and efficacy in HIV patients switching from triple therapy to lopinavir/ritonavir monotherapy: A randomized clinical trial.Analysis of possible drug-drug interactions between ritonavir and other antiretrovirals in a section of the private health care sector in South Africa.

P2860

Q33766361-29A22CE2-8F69-4C38-9DC9-0A655674B5DF Q34349192-C1516683-5C6C-4B3E-BDAA-A59F6AE20778 Q35363679-30ED366D-0F49-4529-AC72-BF89B3EE6E9A Q35557224-B6B3847F-01CD-4A88-BDD9-66B6BA33A310 Q35973937-D5C303F9-C434-4CBE-8AFF-D355C21B7AD2 Q36104280-FC38E4D5-3CE0-4A81-83FE-6068BA8BAE2B Q36439051-039D87F6-80C4-47C0-B988-363667A92E5F Q38263521-9AE1FDFD-2114-433D-B78E-E75C65D643C0 Q40569235-4A829E0D-96C6-43A1-B606-6AB93E01773D Q41066112-E97F7175-4738-4DFF-9D29-759B98114CAB Q42576594-9236BED5-D317-4A71-BE55-F9950AEDC78B Q50040651-084461D6-1AF8-472D-B9AC-232D40A12B32 Q52591808-7D91A2C3-4C46-4081-8F50-1346045DC0C3 Q55208876-170161D9-2031-45DE-98C3-777B8EA8D7AE

P2860

Lopinavir/ritonavir in the treatment of HIV-1 infection: a review.

http://www.wikidata.org/entity/Q37052827

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on October 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Lopinavir/ritonavir in the treatment of HIV-1 infection: a review.

@en

Lopinavir/ritonavir in the treatment of HIV-1 infection: a review.

@nl

type

label

Lopinavir/ritonavir in the treatment of HIV-1 infection: a review.

@en

Lopinavir/ritonavir in the treatment of HIV-1 infection: a review.

@nl

prefLabel

Lopinavir/ritonavir in the treatment of HIV-1 infection: a review.

@en

Lopinavir/ritonavir in the treatment of HIV-1 infection: a review.

@nl

P1433

Q37052827-A5B60A5D-F0E3-497E-B1B5-0AE1D79880A4

P1476

Q37052827-FD892EF0-53A2-4870-A2A6-5977F2CFBF7F

P2093

Q37052827-4FB5E476-F7AF-40FC-A7C6-1E2C90CF99C5

Q37052827-AC128B92-1B25-4B78-B386-8F73AC9B89FC

P2860

Q37052827-07BD60E2-1206-4987-B49A-75A3D5C65555

Q37052827-0EFB9F27-C5A2-4F8B-821C-3DC5C5D702DB

Q37052827-130D5ED9-D80F-4EF1-94C3-EB3CC02DEB1D

Q37052827-19905E0A-9157-4506-9721-1CC0E1398E1E

Q37052827-1AAE665C-5769-4D5A-B645-C0D8A420F89B

Q37052827-1B1BA1DD-530B-4BDD-B844-D0AF7F5D3CCA

Q37052827-1E0E7718-0964-4BAF-8B71-ECFBA42E0EC6

Q37052827-35FAF6DA-87A5-4CB0-AC2B-03EDC3A2D108

Q37052827-382E045F-0014-4C10-B5D0-110CCBBBE5B9

Q37052827-48B4A02A-AE2B-4B87-8053-4C5EF7D9A4E0

P304

Q37052827-0B3C5B66-4A3E-4FB7-BB17-E0F745691A6B

P31

Q37052827-A874E0D8-D6BF-45AE-A754-06669A1C2B1D

P356

Q37052827-D5F447CE-E68B-448C-A897-CADCE7332C19

P433

Q37052827-3CF4C97E-7C55-424D-A77F-59303C0D8EBC

P478

Q37052827-15368170-A891-46DC-BADF-DB1F53EEE58D

P577

Q37052827-D44D0D02-44F1-488B-AD1C-F576550F18F5

P698

Q37052827-252CD625-B38C-4CAD-A4A8-4B963521DDA8

P921

Q37052827-59A89B15-77A2-4B7D-A90E-9639CC56F108

P932

Q37052827-C551085F-F5BB-4006-8A3A-4C5A9B362D2A

P356

P1433

Therapeutics and Clinical Risk Management

P1476

Lopinavir/ritonavir in the treatment of HIV-1 infection: a review

@en

P2093

Ashish Chandwani

http://www.w3.org/2001/XMLSchema#string

Jonathan Shuter

http://www.w3.org/2001/XMLSchema#string

P2860

The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial

ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.

ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.

Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Class-sparing regimens for initial treatment of HIV-1 infection.

Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patients.

Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals.

Virological success of lopinavir/ritonavir salvage regimen is affected by an increasing number of lopinavir/ritonavir-related mutations.

P304

1023-1033

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/TCRM.S3285

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2008-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19209283

http://www.w3.org/2001/XMLSchema#string

P921

P932

2621403

http://www.w3.org/2001/XMLSchema#string